Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer (vol 9, 73, 2023)

被引：0
|
作者：
Fabi, Alessandra
Carbognin, Luisa
Botticelli, Andrea
Paris, Ida
Fuso, Paola
Savastano, Maria Cristina
La Verde, Nicla
Strina, Carla
Pedersini, Rebecca
Guarino, Stefania
Curigliano, Giuseppe
Criscitiello, Carmen
Raffaele, Mimma
Beano, Alessandra
Franco, Antonio
Valerio, Maria Rosaria
Verderame, Francesco
Fontana, Andrea
Haspinger, Eva Regina
Caldara, Alessia
Di Leone, Alba
Tortora, Giampaolo
Giannarelli, Diana
Scambia, Giovanni
机构：
[1] Fondazione Policlinico Universitario A. Gemelli IRCCS,Precision Medicine Unit in Senology
[2] Fondazione Policlinico Universitario A. Gemelli IRCCS,Division of Gynecology Oncology, Department of Woman and Child Health and Public Health
[3] University of Rome,Medical Oncology Unit, La Sapienza
[4] Medical Oncology Unit,Department of Oncology and Hemato
[5] A.O.U. San Giovanni di Dio e Ruggi D’Aragona,Oncology
[6] Medical Oncology Unit,Department of Medical Oncology1
[7] ASST Fatebenefratelli Sacco PO Luigi Sacco - Polo Universitario,Breast Unit, Department of Women, Children and Public Health Sciences
[8] Medical Oncology Unit Azienda Socio-Sanitaria Territoriale Cremona,Medical Oncology, Department of Translational Medicine and Surgery
[9] Medical Oncology Unit ASST Spedali Civili,Epidemiology and Biostatistics Facility
[10] Medical Oncology Unit Santa Maria della Misericordia Hospital,undefined
[11] University of Milan,undefined
[12] Division of Early Drug Development,undefined
[13] European Institute of Oncology,undefined
[14] IRCCS,undefined
[15] Presidio Cassia Sant’andrea,undefined
[16] Dipartimento Oncologico,undefined
[17] Asl Roma1,undefined
[18] Città della Salute e della Scienza Hospital,undefined
[19] Fondazione Policlinico Universitario Agostino Gemelli IRCCS,undefined
[20] Medical Oncology,undefined
[21] Policlinico Universitario P. Giaccone,undefined
[22] Medical Oncology,undefined
[23] AO Riuniti Villa Sofia,undefined
[24] Cervello,undefined
[25] Medical Oncology Unit 2,undefined
[26] Azienda Ospedaliero-Universitaria Pisana,undefined
[27] Azienda Sanitaria dell’Alto Adige – Ospedale di Merano,undefined
[28] Santa Chiara Hospital,undefined
[29] Medical Oncology,undefined
[30] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[31] Università Cattolica del Sacro Cuore,undefined
[32] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined
[33] Università Cattolica del Sacro Cuore,undefined
来源：
NPJ BREAST CANCER | 2024年 / 10卷 / 01期
关键词：
D O I：
10.1038/s41523-024-00619-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1
    Huang, Min
    O'Shaughnessy, Joyce
    Haiderali, Amin
    Pan, Wilbur
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    Fasching, Peter A.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 45 - 52
  • [32] First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis (vol 32, pg 983, 2021)
    Emens, L. A.
    Adams, S.
    Barrios, C. H.
    Dieras, V.
    Iwata, H.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V.
    Swat, A.
    Kaul, M.
    Molinero, L.
    Patel, S.
    Chui, S. Y.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 (12) : 1650 - 1650
  • [33] First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis (vol 32, pg 983, 2021)
    Emens, L. A.
    Adams, S.
    Barrios, C. H.
    Dieras, V.
    Iwata, H.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V.
    Swat, A.
    Kaul, M.
    Molinero, L.
    Patel, S.
    Chui, S. Y.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 (10) : 1308 - 1308
  • [34] The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
    Qiao Li
    Jiaxuan Liu
    Qingyuan Zhang
    Quchang Ouyang
    Yang Zhang
    Qiang Liu
    Tao Sun
    Feng Ye
    Baochun Zhang
    Summer Xia
    Bangyong Zhang
    Binghe Xu
    Nature Communications, 15
  • [35] The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial
    Li, Qiao
    Liu, Jiaxuan
    Zhang, Qingyuan
    Ouyang, Quchang
    Zhang, Yang
    Liu, Qiang
    Sun, Tao
    Ye, Feng
    Zhang, Baochun
    Xia, Summer
    Zhang, Bangyong
    Xu, Binghe
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [36] Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)
    Schmid, Peter
    Cortes, Javier
    Robson, Mark
    Iwata, Hiroji
    Hegg, Roberto
    Verma, Sunil
    Nechaeva, Marina
    Xu, Binghe
    Haddad, Vincent
    Imedio, Esteban Rodrigo
    Schiavon, Gaia
    Foxley, Andrew
    Park, Yeon Hee
    CANCER RESEARCH, 2020, 80 (04)
  • [37] A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
    Schmid, Peter
    Cortes, Javier
    Robson, Mark E.
    Iwata, Hiroji
    Hegg, Roberto
    Nechaeva, Marina
    Xu, Binghe
    Verma, Sunil
    Haddad, Vincent
    Imedio, Esteban Rodrigo
    Schiavon, Gaia
    Foxley, Andrew
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS ≥50%), advanced NSCLC in Japan
    Goto, Y.
    Santorelli, M. L.
    Taniguchi, K.
    Kamitani, T.
    Irisawa, M.
    Kanda, K.
    Abe, M.
    Burke, T.
    Nokihara, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1009
  • [39] Pembrolizumab plus chemotherapy combination - first line in PD-L1 positive (CPS ≥ 10) metastatic and advanced triple-negative breast cancer
    Loison, Rebecca
    Loirat, Delphine
    BULLETIN DU CANCER, 2022, 109 (04) : 387 - 389
  • [40] Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC).
    Cortes, Maria
    Salgado, Alfonso Cortes
    Murillo, Serafin Morales
    Blancas, Isabel
    Cortez, Patricia
    Plaza, Isabel Calvo
    Fernandez, Nieves Diaz
    Martinez-Bueno, Alejandro
    Ruiz-Borrego, Manuel
    Blanch, Salvador
    Llabres, Elisenda
    Marme, Frederik
    Schmid, Peter
    Guarneri, Valentina
    Gligorov, Joseph
    Perez-Garcia, Jose Manuel
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Cussac, Antonio Llombart
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345